I want to share with you the story of my approach to two of my patients being seen for overactive bladder symptoms of urgency and frequency during the day and night. I thought you might be interested in their stories as what I found to be successful treatments were not an approach often recommended. Their symptoms had defied most treatments.

The first patient was James, a 74-year-old man who was referred for Percutaneous tibial nerve stimulation (PTNS) treatments, having failed 2 injections of Botox and multiple overactive bladder (OAB) medications. He had refused an Interstim implant. James was tolerating his
Nocturia is a symptom reported by patients way too often.  As an expert in urology, I see the impact that nocturia has on both men and women, many of whom have been seeking help for a long time. I am leading this Center of Excellence to broaden awareness of nocturia and bring new treatments to patients. My practice is a tertiary, specialized practice and most of my patients have seen multiple providers prior to being referred. In the case of nocturia, roughly 40% do not see an improvement in symptoms with current treatments, although these treatments improve other bladder-related symptoms. People arrive in my office, desperately seeking relief from getting up in the middle of the night – twice or more – to urinate.
Austin, TX (UroToday.com) Dr. Kenneth M Peters and colleagues presented the results from the single-arm, open-label Phase 2 clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI). The first clinical trial to evaluate an orally-administered selective androgen receptor modulator (SARM) for SUI.  Enobosarm, which is an oral selective androgen receptor modulator, given as an androgenic agent to modulate the pelvic floor and urinary sphincter was given to 17 post-menopausal women with stress predominant urinary incontinence were given the drug for 12 weeks.  The primary endpoint was the number of stress incontinence episodes per day on the 3−day voiding diary. Secondary endpoints include pad weights, BST, and quality of life (QOL) instruments (MESA, PGI−S, PGI−I, UDI−6, IIQ−7, and FSFI). Follow up was up to 40 weeks.